Following treatment with both fostamatinib regimens , a statistically significant difference in the ACR@ improvement response was achieved at week @ as compared with that in patients receiving placebo ( @ % -LSB- group A -RSB- and @ % , -LSB- group B -RSB- versus @ % ; P < @ and P = @ , respectively ) , but there was no statistically significant difference in the SHS between either fostamatinib group and placebo ( P = @ and P = @ , respectively ) .